First-line treatment of non-small cell lung cancer PD-1/CTLA-4 immunocombination therapy is superior to chemotherapy

An exploratory analysis of patients with pD-L1 that was not expressed in part 1b showed that Opdivo's combination with low-dose Yervoy also provided survival benefits to patientsThe company looks forward to releasing the full results of Part 1 of the CheckMate 227 Study at an upcoming medical conferencelung cancer is one of the leading causes of cancer death in the worldMore people die each year from lung cancer than colon, breast and prostate cancer combinedLung cancer is mainly divided into small cell lung cancer and NSCLCNSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer patientsIn the United States, the five-year survival of confirmed lung cancer patients is about 18 percentOpdivo and Yervoy are immunocheckpoint inhibitors developed by BMSOpdivo is an anti-PD-1 monoclonal antibody, while Yervoy is an anti-CTLA-4 monoclonal antibodyThis dual checkpoint inhibitor combination therapy has been FDA-approved for first-line treatment of patients with advanced renal cell carcinoma with moderate and high risk, as well as patients with passing colorectal cancer who have been treated with MSI-H/dMMRCheckMate 227 is the first to confirm that lung cancer patients use a dual immunotherapy combination that can obtain a phase 3 clinical trial with a higher total lifetime than chemotherapyDrMartin Reck, a CheckMate 227 researcher at the Grosshansdorf Lung Research Center in Germany, said: "In the 1a section of checkMate 227 clinical studies, the results of opdivo's combination of treatments with Yervoy are expected to provide a 'no chemotherapy-free' treatment for patients with first-line lung cancer and confirm that they can benefit patients with better total survival benefits than chemotherapyI am equally pleased to see that patients benefit from PD-L1 expression or notI look forward to seeing all the data from the study in the futurealso announced that, regardless of PD-L1 status, Part 2 of the CheckMate 227 trial, Opdivo plus chemotherapy, did not reach the pre-specified primary endpoint of OS relative to chemotherapyoriginal title: Express, first-line treatment of lung cancer, PD-1/CTLA-4 immunocombination therapy is superior to chemotherapy